Fresh off presentations this month at the American Society of Clinical Oncology in Chicago and the European Hematology Association in Stockholm that confirmed continued progress in its late-stage pipeline, TG Therapeutics Inc. struck a deal to collaborate on the development and commercialization of a preclinical anti-CD47/anti-CD19 bispecific antibody discovered by Novimmune SA. The companies will jointly advance the fully human IgG1, known as TG-1801 (previously NI-1701), on a global basis with a focus on hematologic B-cell malignancies.